MSCI vs REPL · P/E 37, rev $2.86B vs $825.7M cap
MSCI Inc (MSCI) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
MSCI Inc (MSCI) is a financial data & stock exchanges company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported MSCI revenue for 2024-12-31 was $2.86B. Net income was $1.11B. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. MSCI currently screens at market cap $46.82B and trailing P/E 36.8.
REPL does not have a complete income-statement cache yet.
MSCI currently screens at market cap $46.82B and trailing P/E 36.8. REPL currently screens at market cap $825.7M.
Not investment advice. Open the MSCI and REPL stock pages for the full models.
Not investment advice.